Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Scilex Holding Company (SCLXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: SCLXW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -53.83% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.14 | 52 Weeks Range 0.04 - 0.52 | Updated Date 06/14/2025 |
52 Weeks Range 0.04 - 0.52 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -146.93% | Operating Margin (TTM) -557.51% |
Management Effectiveness
Return on Assets (TTM) -69.26% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 4990167 |
Shares Outstanding - | Shares Floating 4990167 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Scilex Holding Company
Company Overview
History and Background
Scilex Holding Company is focused on developing, manufacturing and commercializing non-opioid therapies for patients with acute and chronic pain. It was founded as a subsidiary of Sorrento Therapeutics, and later became a separate publicly traded company.
Core Business Areas
- Non-Opioid Pain Management: Focuses on developing and commercializing non-opioid pain management solutions. This segment involves research, development, and commercialization of therapies like ZTlido and potentially other products.
- Development and Manufacturing: Handles the development and manufacturing aspects of Scilex's products, ensuring a consistent supply of high-quality medications.
Leadership and Structure
Dr. Henry Ji is the Chairman and CEO. The company has a board of directors overseeing its operations and strategic direction. Organizational structure is typical of a publicly traded pharmaceutical company, with departments for research, development, manufacturing, commercialization, and finance.
Top Products and Market Share
Key Offerings
- ZTlido: ZTlido is a lidocaine topical system for the relief of post-herpetic neuralgia (PHN). Market share data varies, but it competes in the topical pain relief market. Competitors include Lidoderm (Endo International) and generic lidocaine patches.
- SP-102 (SEMDEXA): SP-102 (SEMDEXA) is a non-opioid injectable corticosteroid for the treatment of lumbosacral radicular pain, or sciatica. Phase III trials are underway. Competitors will include other injectable steroids and pain management therapies for sciatica.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly in the pain management sector, is competitive and heavily regulated. There is a growing demand for non-opioid pain management solutions due to the opioid crisis.
Positioning
Scilex is positioned as a company focused on non-opioid pain management, addressing a critical need in the market and differentiates itself by focusing on developing and commercializing innovative and non-addictive pain therapies. With the ongoing opioid crisis, this positioning offers a significant advantage.
Total Addressable Market (TAM)
The TAM for pain management is estimated to be in the tens of billions of dollars annually. Scilex's position with novel non-opioid treatments allows it to capture a significant portion of this market as traditional opioids fall out of favor.
Upturn SWOT Analysis
Strengths
- Focus on non-opioid pain management
- ZTlido already on the market
- SP-102 (SEMDEXA) undergoing late-stage clinical trials
- Experienced management team
Weaknesses
- Reliance on key products
- Limited revenue stream currently
- Dependence on funding for R&D
- Smaller size compared to major pharmaceutical players
Opportunities
- Growing demand for non-opioid pain treatments
- Potential FDA approval of SP-102
- Partnerships with larger pharmaceutical companies
- Expansion into new markets
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and clinical trial risks
- Generic competition for ZTlido
- Changing healthcare landscape
Competitors and Market Share
Key Competitors
- Endo International (ENDP)
- Teva Pharmaceutical Industries (TEVA)
- Pacira BioSciences (PCRX)
Competitive Landscape
Scilex faces competition from larger, established pharmaceutical companies. Its competitive advantage lies in its focus on non-opioid therapies and its pipeline of innovative products. The smaller market capitalization can hinder them from competing.
Major Acquisitions
Vascular Therapies, Inc.
- Year: 2024
- Acquisition Price (USD millions): 15
- Strategic Rationale: Strengthen pipeline with non-opioid therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to the sales of ZTlido and development of other products.
Future Projections: Future growth is contingent on the successful commercialization of SP-102 and expansion of ZTlido's market share. Analyst estimates would provide quantitative future projections.
Recent Initiatives: Focus on the clinical development of SP-102 and expansion of their product pipeline.
Summary
Scilex Holding Company is a pharmaceutical company focused on non-opioid pain management and is positioned to be successful as the opioid crisis encourages new alternative therapies. Its strength lies in its specialization in non-opioid therapies and an experienced management team, however it currently has a very limited revenue stream. The company's future relies on successful clinical trials and commercialization of SP-102 (SEMDEXA), where regulation and competition is fierce.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Publicly available information
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions and company performance can change rapidly. Financial data and metrics will vary and should be confirmed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scilex Holding Company
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2021-03-08 | President, CEO & Director Mr. Jaisim Shah | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 111 | Website https://www.scilexholding.com |
Full time employees 111 | Website https://www.scilexholding.com | ||
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; and Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA. Scilex Holding Company is headquartered in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.